How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?
Representing the landscapes of IC and atherosclerosis prevention/lipid management, you manage a broad spectrum of “clinical signatures” amenable to PCSK9-based intervention. How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?
Created by
Presenter
Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular ProgramsBrigham and Women’s HospitalHeart and Vascular CenterProfessor of Medicine, Harvard Medical SchoolBoston, USA
Atherosclerosis Prevention
Paul Ridker, MD,
Eugene Braunwald Professor
Harvard Medical School
Division of Cardiovascular Medicine
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Boston, MA